Streetbeat News

Analyst Ratings

COWZ

DIVB

DXJ

FXU

ICF

IYK

JAAA

SCHD

TLT

VTV

XLP

XLRE

XLU

As the Federal Reserve shifts to a more accommodative monetary policy, analysts recommend ETFs in utilities, real estate, consumer staples, and more. BofA suggests focusing on defensive sectors and quality yield opportunities, with specific ETF recommendations across various asset classes.

Portfolio Pulse from Piero Cingari

September 17, 2024 | 3:29 pm

GOSS

HC Wainwright & Co. has reiterated its Buy rating for Gossamer Bio, maintaining a price target of $10. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:28 pm

OZK

Raymond James analyst Michael Rose has downgraded Bank OZK from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:28 pm

NGD

Scotiabank analyst Eric Winmill has maintained a Sector Outperform rating on New Gold (AMEX:NGD) and raised the price target from $2.75 to $3.25.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:27 pm

NYCB

Raymond James analyst Steve Moss has upgraded New York Community Bancorp (NYSE:NYCB) from an Underperform to a Market Perform rating.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:26 pm

LIVN

LivaNova shares rose following an upgrade by Baird from Neutral to Outperform, with a price target increase from $55 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:26 pm

BMRN

Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $95 to $78.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:25 pm

DCOM

Raymond James has upgraded Dime Community Bancshares to a Strong Buy and increased its price target to $35, indicating a positive outlook for the stock.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:24 pm

ACN

Citigroup analyst Ashwin Shirvaikar has maintained a Buy rating on Accenture (NYSE:ACN) and raised the price target from $350 to $405.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:22 pm

ASND

Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma and increased the price target from $178 to $207.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:21 pm